Sponsors Want Therapeutic Experience
On several occasions each year, Industry Standard Research (ISR) has the opportunity to speak with sponsor companies about their outsourcing practices.
On several occasions each year, Industry Standard Research (ISR) has the opportunity to speak with sponsor companies about their outsourcing practices. One common topic is CRO selection. Almost invariably sponsors tell us that Therapeutic Expertise is the single most important criterion for selecting a partner for clinical research. In a recent study, however, we also decided to ask which attributes were becoming more important in their selection of service providers.
ISR's data show that not only is Therapeutic Expertise important in today's environment, it is becoming increasingly so; and if our sample is any indication, Oncology and CNS are the areas of focus.
Requirements Evolve for Service Providers
But here's the real news—and the challenge for CROs—sponsors indicate that they want this additional expertise at lower costs. Alongside Therapeutic Expertise, Low Cost is expected to surge as a significant driver of CRO selection. This finding is new in our research. Historically, low cost has shown up 4th or 5th among selection drivers behind characteristics such as Project Manager Quality and Project Team Chemistry, but this appears to be changing.
As sponsors sharpen their pencils, the pressure will increase on CROs to demonstrate value like never before.—Industry Standard Research, www.ISRreports.com
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
